TAC, my main thought is that this reaffirms something that we have discussed here numerous times. Big pharma is not shy about investing in new technologies. The article you posted states Halozyme stands to make 500 million plus royalties from the deal. The company, which I don't believe makes money, has their stock trading at 7.00 per share. It is valued at about 700 million dollars.!! As it could one day relate to Fuse, well, as they say, do the math!